Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, Sören, Bykov, Vladimir J.N., Ali, Dina, Andrén, Ove, Cherif, Honar, Tidefelt, Ulf, Uggla, Bertil, Yachnin, Jeffrey, Juliusson, Gunnar, Moshfegh, Ali, Paul, Christer, Wiman, Klas G., Andersson, Per-Ola·2012·Journal of Clinical Oncology
DOI 10.1200/jco.2011.40.7783

Cited by (406)

Items 301–400 of 406

  1. Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants
    Adam J. Nagourney, Joshua B. Gipoor, Steven Scott Evans, Paulo D’Amora, Max Duesberg, Paula J. Bernard, Federico R. Francisco, Robert Alan Nagourney · 2023 · Genes
  2. Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties
    Sara Ibrahim Omar, Jack A. Tuszyński · 2014 · Chemical Biology & Drug Design
  3. Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets
    Jessica I. Hoell, Sebastian Ginzel, Michaela Kuhlen, Andreas Kloetgen, Michael Gombert, Ute Fischer, Daniel Hein, Salih Demir, Martin Stanulla, Martin Schrappe et al. · 2019 · Blood Advances
  4. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53
    Stephen Lee Abrams, Shaw M. Akula, Alberto Maria Martelli, Lucio Cocco, Stefano Ratti, Massimo Libra, Saverio Candido, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak et al. · 2021 · Advances in Biological Regulation
  5. Innovative Therapeutic Approaches for the Treatment of the Ocular Morbidities in Patients with EEC Syndrome
    Vanessa Barbaro, Filippo Bonelli, Stefano Ferrari, Giulia La Vella, Enzo Di Iorio · 2023 · Cells
  6. DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia
    Saket V. Mishra, Archisman Banerjee, Debashmita Sarkar, Vishnuvarthan Thangarathnam, Bhausaheb Pandurang Bagal, Syed K. Hasan, Shilpee Dutt · 2024 · Journal of Cell Science
  7. Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells
    Masashi Idogawa, Tomoko Ohashi, Jun Sugisaka, Yasushi Sasaki, Hiromu Suzuki, Takashi Tokino · 2014 · Oncotarget
  8. Apoptosis in Cancer
    Zahid Hussain Siddik · 2014 · Elsevier eBooks
  9. DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia
    Upendarrao Golla, Melanie A. Ehudin, Charyguly Annageldiyev, Zheng Zeng, Diwakar Bastihalli Tukaramrao, Anna Y. Tarren, Abhijit A. Date, Irina A. Elcheva, Arthur S Berg, Shantu Amin et al. · 2021 · Cancers
  10. What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?
    Chen Wang, David A. Sallman · 2022 · The Cancer Journal
  11. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions
    Abhishek Maiti, Naval Guastad Daver · 2022 · Journal of Clinical Oncology
  12. Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models
    Toby James Phesse, Victoria Marsh Durban, Owen James Sansom · 2017 · Carcinogenesis
  13. MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
    Yan Yu Zhu, Herui Wang, Asha Thuraisamy · 2019 · Elsevier eBooks
  14. PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells
    Chayanit Piyawajanusorn, Yingpinyapat Kittirat, Prakasit Sa-Ngiamwibool, Attapol Titapun, Watcharin Loilome, Nisana Namwat · 2019 · Cancer Genomics & Proteomics
  15. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
    Jan Philipp Bewersdorf, Amer Methqal Zeidan · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
  16. Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
    Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Giorgina Specchia, Pellegrino Musto, Francesco Albano · 2021 · Cancers
  17. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics
    Hannah H Asghari, Chetasi Talati · 2020 · Current Opinion in Hematology
  18. Dual-functional copper nanoplatform potentiates cuproptosis through p53 reactivation and metabolic reprogramming
    Lele Ma, Huiying Zheng, Wanlin Xie, Weidi Sun, Qunying Yuan, Kun Song, Peiyu Xi, Fengli Qu, Hui Zhang · 2025 · Journal of Colloid and Interface Science
  19. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia
    Mihir Shukla, Maher Abdul‐Hay, Jun‐Hui Choi · 2024 · Biomedicines
  20. SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes
    Brandon J. Aubrey, Andrew Mark Brunner · 2022 · Clinical Lymphoma Myeloma & Leukemia
  21. Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours
    Matteo Molica, Salvatore Perrone · 2022 · Expert Review of Hematology
  22. Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
    Iulianna C. Taritsa, Eric T. Fossel · 2025 · Frontiers in Pharmacology
  23. Topological properties and in vitro identification of essential nodes of the Paclitaxel and Vincristine interactomes in PC-3 cells
    Claudia Delgado-Carreño, Gina Méndez-Callejas · 2019 · Biomedical Journal
  24. Drugging the Master Regulator TP53 in Cancer: Mission Possible?
    Giovanni Blandino · 2021 · Journal of Clinical Oncology
  25. Stability of p53 oligomers: Tetramerization of p53 impinges on its stability
    Johnson Wahengbam Luwang, Aadithye R. Nair, Ramanathan NATESH · 2021 · Biochimie
  26. What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias
    Marco Pizzi, Carmela Gurrieri, Attilio Orazi · 2023 · Hemato
  27. Tumorigenic p53 mutants undergo common structural disruptions including conversion to α‐sheet structure
    Dennis Bromley, Valerie Daggett · 2020 · Protein Science
  28. Combined treatment with p53-activating drug APR-246 and a phosphatidylserine-targeting antibody, 2aG4, inhibits growth of human triple-negative breast cancer xenografts
    Yayun Liang, Cynthia L Besch-Williford, Benford Mafuvadze, Rolf A. Brekken, Salman M. Hyder · 2020 · Cancer Reports and Reviews
  29. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms
    Sangeetha Venugopal, Sanam Loghavi · 2023 · Pathobiology
  30. What biomarkers (if any) for precise medicine?
    Sabrina Strano, Paola C. Muti, Giovanni Blandino · 2015 · Aging
  31. TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds
    Rituraj Chakraborty, Anupam Dutta, Rupak Mukhopadhyay · 2025 · Clinical & Translational Oncology
  32. Tumor microenvironment noise-induced polarization: the main challenge in macrophages’ immunotherapy for cancer
    Jesús Sierra, Ugo Avila-Ponce de León, Pablo Padilla-Longoria · 2025 · Molecular and Cellular Biochemistry
  33. p53-dependent cell cycle checkpoint after DNA damage and its relevance to PARP1
    Tadashige Nozaki, Mitsuko Masutani · 2018 · Research and Review Insights
  34. Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma
    Ali J. Hajiran, Taylor Bracco, Logan W. Zemp, Philippe E. Spiess · 2020 · Urologic Oncology Seminars and Original Investigations
  35. Molecular and therapeutic bases of cancer
    Guadalupe Rosario Fajardo-Orduña, D. Chamorro-Plata · 2021 · Elsevier eBooks
  36. Differential roles of the Wip1–p38–p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas
    Chenyang Xu, Takeo Minaguchi, Nan Qi, Kaoru Fujieda, Asami Suto, Hiroya Itagaki, Ayumi Shikama, Nobutaka Tasaka, Azusa Akiyama, Sari Nakao et al. · 2022 · World Journal of Surgical Oncology
  37. Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
    Wafik S. El‐Deiry · 2023 · Cancer Research
  38. Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
    Jan Philipp Bewersdorf, Zhuoer Xie, Amer Methqal Zeidan · 2023 · The Cancer Journal
  39. A step closer toward therapies for p63-related disorders
    Huiqing Zhou, Daniel Aberdam · 2013 · Rare Diseases
  40. Breast Cancer Therapy by Small-Molecule Reactivation of Mutant p53
    Simon H. Slight, Salman M. Hyder · 2025 · Current Oncology
  41. Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
    Radhika Bansal, Sagar Rakshit, Weiguo Han, Shaji Kunnathu Kumar · 2021 · touchREVIEWS in Oncology & Haematology
  42. Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Marie Gaillard, Peter Van Eyken, Geert Verswijvel, Kurt Van der Speeten · 2023 · Indian Journal of Surgical Oncology
  43. TP53 structure–function relationships in metastatic castrate‐sensitive prostate cancer and the impact of APR‐246 treatment
    Tung Hoang, Philip Anthony Sutera, Triet Nguyen, Jinhee Chang, Shreya Jagtap, Yang Song, Amol Carl Shetty, Dipanwita D. Chowdhury, Aaron Chan, Francesca A. Carrieri et al. · 2023 · The Prostate
  44. Advances in the management of higher-risk myelodysplastic syndromes: future prospects
    Georgina Gener‐Ricos, Juan José Rodríguez‐Sevilla, Samuel Urrutia, Álex Bataller, Alexandre Bazinet, Guillermo Garcia‐Manero · 2024 · Leukemia & lymphoma/Leukemia and lymphoma
  45. A review of first-in-human small molecule oncology clinical trials
    Daniel Greenwood, Ian James Stratford, Steven W. Booth · 2016 · International Journal of Clinical Trials
  46. Precision Medicine Based on Next-Generation Sequencing and Master Controllers
    Katerina Dukleska, Charles J. Yeo, Michael Jon Pishvaian, Jonathan Robert Brody · 2018 · Springer eBooks
  47. The Cell Cycle and Androgen Signaling Interactions in Prostate Cancer
    Simone de Brot, Nigel Patrick Mongan · 2017 · Molecular pathology library
  48. Caractérisation génomique des carcinomes épidermoïdes de la tête et du cou : impact et enjeux pour la prise en charge thérapeutique
    Esma Saâda-Bouzid, Gerard Alain Milano, Juliette Thariat · 2018 · Bulletin du Cancer
  49. Targeting TP53 Mutations in Myelodysplastic Syndromes
    David Andrew Sallman · 2018 · The Hematologist
  50. Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment
    Kazuhito Suzuki, Shingo Yano · 2023 · Cancers
  51. Precision medicine for TP53-mutated acute myeloid leukemia
    Marte Karen Brattås, Håkon Reikvam, Tor Henrik Anderson Tvedt, Øystein Bruserud · 2019 · Expert Review of Precision Medicine and Drug Development
  52. Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
    Zsolt Szakács, Hussain Alizadeh · 2022 · Hematológia–Transzfuziológia
  53. Structural and functional studies of proteins in cell signaling and cancer
    Rebecca Dovega · 2014 · Figshare
  54. p53 mutation-associated prognosis across cancer types underlines hematological malignancy as an applicable cancer type to p53-rescue therapy
    Shujun Xiao, Jiaqi Wu, Kai Wei Tan, Sujiang Zhang, Yuting Dai, Jiarui Wu, Jiale Wu, Xinle Han, Derun Zheng, Xin Wang et al. · 2025 · Fundamental Research
  55. Pharmacologic progress in higher-risk MDS: an uphill battle
    Alain Antoine Mina, Amer Methqal Zeidan · 2026 · Expert Opinion on Pharmacotherapy
  56. Reactivating p53 mutants selectively in patients
    Shuo Chen, H. Michael Shepard, Min Lu · 2026 · Cancer Cell
  57. Wild-Type p53 Protein Enhances APR-246-Induced Cytotoxicity in Acute Myeloid Leukemia and Normal Hematopoietic Stem/Progenitor Cells
    John Bradley Cart, David Zhu, Lucas Norris, Sadhna O. Piryani, Li-Chan Chang, Christine Elissa Eyler, Chang‐Lung Lee · 2026 · International Journal of Molecular Sciences
  58. Drugging p53 mutants: Recent advances using small-molecule modulation strategies
    Elizabeth A. Lopes, Tomás G. Monteiro, Maria M. M. Santos · 2026 · European Journal of Medicinal Chemistry
  59. Targeting apoptosis is the major battle field for killing cancers
    Xiaochun Liu · 2015 · World Journal of Translational Medicine
  60. Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy
    Arutselvan Natarajan, Husam A. Babikir, Ramasamy Paulmurugan, Tarik F. Massoud · 2021 · Elsevier eBooks
  61. Research Progress of Mutant p53 as a Potential Therapeutic Target for Breast Cancer
    俊臻 周 · 2021 · Advances in Clinical Medicine
  62. Prognostic significance of tumor suppressor protein p53 in prostate cancer
    Sarra Ben Rejeb, Nadia Kouki, Sirine Elfekih, Ines Cherif, Hassen Khouni · 2024 · La Tunisie Médicale
  63. Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer
    Mikael von Euler, Klas G. Wiman, Hani Gabra, James D. Brenton, Bristi Basu, Ignace B. Vergote, Charlie Gourley, Austin Smith, Jessica Alfredsson, Nina Mohell et al. · 2015 · Cancer Research
  64. Studies of New Signal Transduction Modulators in Acute Myeloid Leukemia
    Anna Eriksson · 2012 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
  65. TP53 mutations in myelodysplastic syndromes with deletion of 5q
    Leonie Saft · 2013 · Figshare
  66. Molecular genetic studies on Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia - with focus on prognostic markers
    Kerstin Willander · 2014 · Linköping University Electronic Press eBooks
  67. 4th international conference on tumor progression and therapeutic resistance: meeting report
    Varun V. Prabhu, Wafik S. El‐Deiry · 2015 · Cancer Biology & Therapy
  68. Mechanisms of p53-mediated intrinsic and extrinsic tumor suppression
    Hai Li · 2014 · Figshare
  69. How far is the horizon? From current targets to future drugs in advanced renal cancer
    Stephan Kruck, Axel S. Merseburger, Arnulf Stenzl, Jens Bedke · 2013 · World Journal of Urology
  70. Mutacje TP53 w nowotworach hematologicznych
    M Zajac, Krzysztof Giannopoulos · 2015 · Acta Haematologica Polonica
  71. Mechanisms of p53-mediated Intrinsic and Extrinsic Tumor Suppression
    Galina Selivanova, Petter Höglund, Giulia Piaggio, Regina Elena, Teresa Pereira, Anthony R. Wright, Claes Wadelius, Uppusala Universitit · 2014
  72. Review Article A review of first-in-human small molecule oncology clinical trials
    Daniel J.H. Greenwood, Ian James Stratford, Steven W. Booth · 2016
  73. Investigation of novel therapeutic strategies for epithelial ovarian cancer
    Nobuhisa Yoshikawa · 2016 · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
  74. Visual Analytics Methods for Analyzing Molecular Dynamics Simulations of Mutant Proteins
    Dennis Bromley · 2015 · ResearchWorks at the University of Washington (University of Washington)
  75. Characterization and functional analysis of mutant p53 secretome in human cancer
    Reshma Shakya · 2016 · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
  76. Understanding p53 structure and targeting mutant p53 for improved cancer therapy
    Qiang Zhang · 2018 · Figshare
  77. Making sense from nonsense and missense : pharmacological rescue of mutant tumor suppressor p53
    Meiqiongzi Zhang · 2018 · Figshare
  78. Molecular targets and targeted therapy
    Peixin Dong · 2014
  79. Targeted Next-Generation Sequencing in Head and Neck Cancer
    Ingeborg Tinhofer · 2018 · Springer eBooks
  80. Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents
    Yi Liao · 2018 · Human Biology
  81. Transplantation for TP53 mutant MDS: Room for improvement
    Dries Deeren · 2018 · Leukemia Research
  82. As vias de p53/ARF e interferon beta como alvos de terapia gênica de carcinoma colorretal
    Paulo Roberto Del Valle · 2019
  83. Change in mutation frequency at a TP53 hotspot during culture of ENU-mutagenised human lymphoblastoid cells
    Masahiko Watanabe, Masae Toudou, Taeko Uchida, Misato Yoshikawa, Hiroaki Aso, Katsuya Suemaru · 2019 · Mutagenesis
  84. OVER KANSERİ HÜCRELERİNDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİŞEN miRNA EKSPRESYON ANALİZİ
    Nilüfer İmir, Esra Arslan Aydemir, Ece Şimşek · 2020 · Sağlık Bilimleri Dergisi
  85. Promising agents on the horizon
    Alice Soragni, Meghna S. Trivedi · 2020 · Elsevier eBooks
  86. Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia
    Debora Capelli, Francesco Saraceni, Diego Menotti, Alessandro Fiorentini, Attilio Olivieri · 2020 · IntechOpen eBooks
  87. Mutation-dependent treatment approaches for patients with complex multiple myeloma
    Foteini Theodorakakou, Meletios Athanasios Dimopoulos, Efstathios Kastritis · 2021 · Expert Review of Precision Medicine and Drug Development
  88. Updates on Acute Myeloid Leukemia Management in older patients
    Salman Otoukesh, Julio Alvarenga Thiebaud, Guido Marcucci, Monzr M. Al Malki · 2021 · Trends in Transplantation
  89. Three essays on licensing university inventions
    Radu Munteanu · 2007 · eScholarship (California Digital Library)
  90. Targeting MDM2, the antagonist of the tumor suppressor p53
    Anusha Sriraman · 2018 · eDiss (Georg-August-Universität Göttingen)
  91. Precision Medicine Based on Next Generation Sequencing and Master Controllers
    Katerina Dukleska, Charles J. Yeo, Michael Jon Pishvaian, Jonathan Robert Brody · 2017 · Springer eBooks
  92. TP53
    Kensuke Kojima, Michael Andreeff · 2015 · Wiley eBooks
  93. P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cells
    Ibtehal Mohammed, Ali Haider Alhammer, Inam Sameh Arif · 2023
  94. RAD54L Is a Prognostic Biomarker and Demonstrate Correlation With Drug Sensitivity in Hepatocellular Carcinoma
    Tingting You, Hui Jun Tang, Hui Ge, Chunmei Bai, Jianfeng Zhou · 2025 · Cell Biology International
  95. Dynamic ubiquitination networks in liver cancer: decoding E3 ligases and deubiquitinases as gatekeepers of therapeutic resistance
    Nuo Xu, Yun Tong, Kexin Ma, Lihan Jiang, Wenjie Zheng · 2025 · Medical Oncology
  96. Experimental Treatment in Prostate Cancer: Gene Profiling and Genetic
    Henk G. van der Poel · 2025 · Springer eBooks
  97. Comparative Study of a Variant Neural Relational Inference Deep Learning Model and Dynamical Network Analysis for p53-DNA Allosteric Interactions
    Haoxin Sun, Jingbo Wei, Yiming Tang, Tianjing Guo, Guanghong Wei, Jiangtao Lei · 2025 · Journal of Molecular Biology
  98. Exploring Prima-1MET as a single agent or in combination with tamoxifen in breast cancer cells in vitro
    Ali Haider Alhammer, Shahad Ali Mudhafar, Shaimaa Yousif Abdulfattah · 2025 · European Journal of Pharmacology
  99. Context-dependent rewiring of dual-function proteins in cancer: a sequential strategy to restore apoptosis
    Leon Strządała · 2025 · Frontiers in Oncology
  100. APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti–PD-1 efficacy in bladder cancer
    Chi Zhang, Senming Cao, Guineng Zeng, Yuhao Dong, HongZhao Li, Xin Ma, Xu Zhang, Zhi Li, Yan Huang · 2026 · Scientific Reports